¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Receptors, Tumor Necrosis Factor, Type II"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • mesenchymal tumor
    Áß°£¿±Á¾¾ç
  • mesodermal tumor
    Á߹迱Á¾¾ç
  • metastatic tumor
    ÀüÀÌÁ¾¾ç
  • neuroepithelial tumor
    ½Å°æ»óÇÇÁ¾¾ç
  • nonfunctioning tumor
    ºñ±â´ÉÁ¾¾ç
  • odontogenic tumor
    Ä¡¿ø¼ºÁ¾¾ç
  • organoid tumor
    Àå±â¸ð¾çÁ¾¾ç
  • phyllodes tumor
    ¿±»óÁ¾¾ç
  • polypoid tumor
    Æú¸³¸ð¾çÁ¾¾ç
  • primitive neuroectodermal tumor
    ¿ø½Ã½Å°æ¿Ü¹è¿±Á¾¾ç
  • peripheral primitive neuroectodermal tumor
    ¸»ÃÊ¿ø½Ã½Å°æ¿Ü¹è¿±Á¾¾ç
  • renin-secreting juxtaglomerular tumor
    ·¹´ÑºÐºñÅ丮°çÁ¾¾ç, ·¹´ÑºÐºñ»ç±¸Ã¼¿·Á¾¾ç
  • retroperitoneal tumor
    Èĺ¹¸·Á¾¾ç, ¹è¸·µÚÁ¾¾ç
  • solid tumor
    °íÇüÁ¾¾ç
  • solid-cystic tumor
    °íÇü³¶¼ºÁ¾¾ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • gross tumor volume
    ¸Ç´«Á¾¾çüÀû
  • tumor suppressor gene
    Á¾¾ç¾ïÁ¦À¯ÀüÀÚ
  • heterogenous tumor
    ÀÌÁúÁ¾¾ç
  • homologous tumor
    µ¿Á¾Á¾¾ç
  • hormone dependent tumor
    È£¸£¸óÀÇÁ¸Á¾¾ç
  • infiltrating tumor
    ħÀ±Á¾¾ç
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç
  • melatonic neuroectodermal tumor
    ¸á¶ó´Ñ½Å°æ¿Ü¹è¿±Á¾¾ç
  • mesenchymal tumor
    Áß°£¿±Á¾¾ç
  • mesodermal tumor
    Á߹迱Á¾¾ç
  • metastatic tumor
    ÀüÀÌÁ¾¾ç
  • mixed tumor
    È¥ÇÕÁ¾¾ç
  • mixed germ cell tumor
    È¥ÇÕ¹è¾Æ¼¼Æ÷Á¾¾ç
  • tumor marker
    Á¾¾çÇ¥ÁöÀÚ
  • neuroepithelial tumor
    ½Å°æ»óÇÇÁ¾¾ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • C-type virus particle
    CÇü ¹ÙÀÌ·¯½ºÀÔÀÚ.
  • Charcot-Marie type
    »þ¸£ÄÚ-¸¶¸®Çü.
  • Duchenne-Landouzy type
    µÚ½Ã¿£´À-¶õµÎ¿ìÁöÇü.
  • Gougerot-Ruiter type vasculitis
    ±¸Á¦·Î ·çÀÌÅÍ Çü Ç÷°ü¿°
  • L-type chnnels
    L-Çü Åë·Î(÷×ÖØ)
  • Lafora body type of myoclonus
    ¶óÆ÷¶ó üÇü ¸¶ÀÌ¿ÀŬ·Î´©½º.
  • Lutheran s type
    ·çÅ×¶õÇü.
  • Mobitz type I SA block
    ¸ðºñÃ÷ ¥°Çü µ¿¹æÂ÷´Ü.
  • Mobitz type II AV block
    ¸ðºñÃ÷ ¥±Çü ¹æ½ÇÂ÷´Ü.
  • Mobitz type II SA block
    ¸ðºñÃ÷ ¥±Çü µ¿¹æÂ÷´Ü.
  • Ogawa type
    ¿À°¡¿ÍÇü
  • RF coil type
    °íÁÖÆÄ ÄÚÀÏ À¯Çü
  • T-type channel
    T-Çü Åë·Î
  • aberrant type
    ÀÌÇü(ì¶úþ)
  • abortive type
    ºÎÀüÇü(ÝÕîïúþ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • anovulatory type
    ¹«¹è¶õÇü
  • association type
    ¿¬»óÀ¯Çü
  • asthenia type
    ¹«·ÂüÇü.
  • atypical type
    ºñÁ¤Çü ÇüÅÂ
  • bell type
    Á¾¸ð¾ç, Á¾Çü.
  • blood group =b. type
    Ç÷¾×Çü(Ì´ËâÌ´).
  • blood group =b. type
    Ç÷¾×Çü(úìäûû¡).
  • blood type
    Ç÷¾×Çü(Ì´ËâÌ´).
  • blood type
    Ç÷¾×Çü(úìäûúþ)
  • body type
    üÇü
  • body type
    üÇü(ô÷úþ).
  • bubble type vaporizer
    ±âÆ÷Çü ±âÈ­±â
  • calcified hypertrophic type
    ¼®È¸È­ºñ´ëÇü
  • catatonic type
    ±äÀåÇü
  • cellular type dermatofibroma
    ¼¼Æ÷Çü ÇǺμ¶À¯Á¾
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • factor XIII
    ÀÎÀÚ(ì×í­) XIII
  • factor XIV
    ÀÎÀÚ(ì×í­) XIV
  • factor F
    ÀÎÀÚ(ì×í­) F
  • factor G
    ÀÎÀÚ(ì×í­) G
  • factor IF
    ÀÎÀÚ(ì×í­) IF
  • factor R
    ÀÎÀÚ(ì×í­) R
  • factor T
    ÀÎÀÚ(ì×í­) T
  • factor theory
    ÀÎÀÚ ÀÌ·Ð(ì×í­×âÖå)
  • factor X
    ÀÎÀÚ(ì×í­) X
  • factor Y
    ÀÎÀÚ(ì×í­) Y
  • fertility factor
    ¼öÁ¤ ÀÎÀÚ (áôïñì×í­)
  • F factor
    F ÀÎÀÚ(ì×í­)
  • F' factor
    F' ÀÎÀÚ(ì×í­)
  • fibrin-stabilizing factor
    ¼¶À¯¼Ò ¾ÈÁ¤È­ÀÎÀÚ(àéë«áÈäÌïÒûùì×í­)
  • Fitzgerald factor
    ÇÍÁ¦¶öµå ÀÎÀÚ(ì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
GRF gastrin-releasing factor; genetically related macrophage factor; gonadotropin-releasing factor; grow...
HSF heat shock factor; hepatocyte stimulatory factor; histamine sensitizing factor; human serum esterase...
LPF leukocytosis-promoting factor; leukopenia factor; lipopolysaccharide factor; localized plaque format...
MIF macrophage inhibitory factor; melanocyte[-stimulating hormone]-inhibiting factor; maximum inspirator...
MRF Markov random field; medical record file; melanocyte-[stimulating hormone]-releasing factor; mesence...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
CR1 C3b-C4b receptors
CB1 cannabinoid 1 receptors
ER, PR Estrogen and progesterone receptors
FcR Fc gamma Receptors
GRPR Gastrin-releasing peptide receptors
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • adenomatoid tumor
    ¼± Á¾¾ç Á¾¾ç, À¯¼±Á¾ Á¾¾ç
    ¼ºÀå ¼Óµµ°¡ ´À¸° ÀÛÀº °áÀýÇüÀÇ ¾ç¼º Á¾¾çÀ̳ª ¶§·Î´Â ¼ö cm±îÁö µÉ ¼ö ÀÖ´Ù. ÀÌ Á¾¾çÀº ºÎ°íȯ Á¾¾ç Áß °¡Àå ÈçÇÏ¸ç ¿©ÀÚ¿¡¼­µµ Àڱà ¶Ç´Â ¼ö¶õ°üÀÇ À帷Ãþ¿¡ ¹ß»ýÇÒ ¼ö ÀÖ´Ù.
  • adrenal cortex tumor
    ºÎ½Å ÇÇÁú Á¾¾ç
  • amelanotic tumor
    ¹«¸á¶ó´Ñ Á¾¾ç
  • benign giant cell tumor
    ¾ç¼º °Å´ë¼¼Æ÷ Á¾¾ç
    1. °ñÀÇ ¾ç¼º °Å´ë¼¼Æ÷Á¾. °ñÀÇ ¾ç¼º Á¾¾çÀÇ Çϳª·Î ³ë¾àÀÚ¿¡°Ô ¸¹À¸¸ç ¹ß»ý ºÎÀ§´Â Àå°ü°ñÀÇ °ñ´Ü¿¡ ¸¹ÀÌ ³ªÅ¸³­´Ù. Á¶Á÷ÇÐÀûÀ¸·Î ¿øÇü, ¹æÃßÇüÀÌ ÀÖ´Ù. ¼¼Æ÷ »çÀÌ¿¡ ÆÄ°ñ¼¼Æ÷¿Í À¯»çÇÑ °Å´ë¼¼Æ÷°¡ È¥ÀçÇÑ´Ù. 2. °ÇÃÊÀÇ ¾ç¼º °Å´ë¼¼Æ÷Á¾. º»·¡ Á¾¾çÀÌ ¾Æ´Ï¸ç, °áÁ¤¼º °ÇÃÊ¿°À» °¡¸®Å°¸ç °ÇÃÊÀÇ ¼¶À¯¼º Á¶Á÷±¸Á¾¿¡ Æ÷ÇԵȴÙ.
  • benign melanocytic tumor
    ¾ç¼º ¸á¶ó´Ñ ¼¼Æ÷Á¾
  • benign vascular tumor
    ¾ç¼º Ç÷°üÁ¾
  • beta cell tumor
    º£Å¸ ¼¼Æ÷Á¾
  • beta-cell tumor
    º£Å¸ ¼¼Æ÷ Á¾¾ç
    µµ¼¼Æ÷ Á¾¾ç Áß °¡Àå ÈçÇÑ Áúº´À¸·Î Àν¶¸° °ú´Ù ºÐºñ°¡ ÀϾ´Ù.
  • bladder tumor
    ¹æ±¤ Á¾¾ç
    ¹æ±¤ º®ÀÇ °¢ Á¶Á÷¿¡ ¹ß»ýÇÏ´Â Á¾¾ç. À¯µÎÁ¾, ¼±Á¾, ±ÙÁ¾, ÇǺξçÁ¾, Áö¹æÁ¾, Ç÷°üÁ¾ µî ¾ç¼ºÀÎ °Í°ú ¾Ï, À°Á¾ µî ¾Ç¼ºÀÎ °ÍÀÌ ÀÖÀ¸¸ç, ¾à 10 %¸¸ÀÌ ¾ç¼ºÀÌ°í ´ëºÎºÐÀÌ ¾Ç¼ºÀ¸·Î ¹ß»ý ¿øÀÎÀº ºÒ¸íÀÌ´Ù. ƯÁ¤ ±âÈ£ À½·á³ª ¾à¹°ÀÇ Àå±â ¿¬¿ë µî¿¡ ÀÇÇÏ´Â °Í°ú ¾Æ´Ò¸°°è ¾àǰÀ» Ãë±ÞÇÏ´Â °øÀå ±Ù·ÎÀÚ¿¡°Ô¼­ º¸°Ô µÇ´Â Á÷¾÷ ¾ÏÀÌ ÁÖ¸ñµÇ°í ÀÖ´Ù. ¶ÇÇÑ ¹æ±¤ Á¾¾çÀº Áß³â ÀÌÈÄ¿¡ Àß ¹ß»ýµÇ¸ç ¿©ÀÚº¸´Ù ³²ÀÚ¿¡°Ô ¸¹´Ù. Ãʱâ Áõ¼¼´Â Ç÷´¢¸¦ º¸ÀÌ´Ù°¡ ÀúÀý·Î ¸ÜÀ¸¸ç, ÀÌ·± ÀÏÀÌ ¹Ýº¹µÇ´Â µ¿¾È¿¡ ¹æ±¤¿°, ½Å¿ì½Å¿°À» º´¹ßÇÏ¿© ¹è´¢Åë, ºó´¢, Ç÷³ó´¢¿Í ¿äÅëÀÌ ³ªÅ¸³­´Ù. ¶§·Î´Â ¹æ±¤ ¾È¿¡ ÀÀÇ÷ÀÌ »ý±â°í ¹æ±¤ Ãⱸ¿¡ Á¾¾çÀÌ »ý°Ü ¹è´¢ Àå¾Ö°¡ ¿À±âµµ ÇÑ´Ù. ¹æ±¤°æ °Ë»ç·Î Áø´ÜÇϸç, ħÀ±¼ºÀÌ °­ÇϹǷΠÁ¶±â Áø´Ü ¹× Á¶±â Ä¡·á°¡ ¹Ù¶÷Á÷ÇÏ´Ù. Ä¡·á¹ýÀ¸·Î´Â ¿©·¯ °¡Áö ºñ´¢±â°úÀû ¼ö¼ú¹ý°ú ¹æ»ç¼± ¿ä¹ýÀÌ ÀÖÀ¸¸ç, Á¾¾çÀÇ ¼º»ó°ú ȯÀÚÀÇ ¿¬·É ¹× Àü½Å »óÅ µî¿¡ µû¶ó¼­ ÀÌ µÎ °¡Áö¸¦ Àû´çÈ÷ ¼¯¾î Ä¡·áÇÏ´Â Ä¡·á¹ýÀ» »ç¿ëÇÑ´Ù. ¾Ç¼ºÀÎ °æ¿ì ¹æÄ¡Çϸé ÇÒ¼ö·Ï ¹æ±¤ÀÇ ÁÖº¯ ¹× ¸Ö¸® ¶³¾îÁø ºÎÀ§¿¡µµ ÀüÀÌÇÏ¿© Ä¡À¯µÇ±â ¾î·Á¿öÁø´Ù. Àç¹ßÇϱ⠽¬¿î ÁúȯÀ̹ǷΠġ·á ÈÄ¿¡µµ 1³â¿¡ 3ȸ Á¤µµ ¹Ý¿µ±¸ÀûÀ¸·Î Á¤±â °ËÁøÀ» ¹Þ¾Æ¾ß Çϸç, Ç÷´¢°¡ ³ªÅ¸³ª¸é Áï½Ã ÁøÂûÀ» ¹Þµµ·Ï ÇÑ´Ù.
  • bluish tumor
    Ǫ¸¥ »ö Á¾¾ç
  • bone tumor
    °ñ Á¾¾ç
    óÀ½¿¡ »À¿¡ ¹ß»ýÇÏ´Â Á¾¾ç. ´Ù¸¥ ºÎÀ§¿¡¼­ ¾ÏÀÌ ÀüÀÌÇÏ´Â Àϵµ ÀÖÀ¸³ª, ´ëºÎºÐÀº Á¶°ñ¼¼Æ÷³ª Á¶Á÷ÀÇ ÀÌ»ó Áõ½Ä¿¡ ÀÇÇÏ¿© »ý±ä´Ù. °ñ Á¶Á÷ ÀÚü¿¡¼­ ¹ß»ýÇÏ´Â Á¾¾çÀ¸·Î´Â °ñÁ¾, ¿¬°ñÁ¾ÀÌ ÀÖ°í, »À¿¡ Æ÷ÇÔµÈ °áÇÕÁ¶Á÷¿¡¼­ ¹ß»ýÇÏ´Â ¼¶À¯Á¾, Ç÷°ü¿¡¼­ ¹ß»ýÇÏ´Â Ç÷°üÁ¾, °ñ¼ö¿¡¼­ ¹ß»ýÇÏ´Â °ñ¼öÁ¾ÀÌ ÀÖ´Ù. °ñ¼öÁ¾À» Á¦¿ÜÇϰí´Â ¸ðµÎ ¾ç¼º Á¾¾çÀ¸·Î »ý¸íÀÇ À§ÇèÀÌ µû¸£´Â ÀÏÀº ¾ø°í °ÅÀÇ Å¸°¢ ¼Ò°ß
  • brenner tumor
    ºê·»³Ê Á¾¾ç
    µå¹® ³­¼Ò Á¾¾çÀÌ´Ù. ¾î¸°ÀÌ¿¡¼­ ³ëÀαîÁö ¸ðµç ¿¬·É¿¡ ¹ß»ýµÇ³ª ´ëºÎºÐÀÌ 50¼¼ ÀÌÈÄ¿¡ »ý±ä´Ù. À°¾ÈÀûÀ¸·Î ´ëºÎºÐ °íÇü¼ºÀÌ°í ´Ü´ÜÇÏ¸ç ¼è¹é»öÀ̳ª µå¹°°Ô ÀÛÀº ³¶¼º ºÎÀ§°¡ Àְųª ¿ÏÀüÇÑ ³¶¼ºÀÏ ¼öµµ ÀÖ´Ù. Å©±â´Â 1cm ¹Ì¸¸ÀÇ ÀÛÀº Á¾¾ç¿¡¼­ ¸Å¿ì Å« Á¾¾ç±îÁö ´Ù¾çÇÏÁö¸¸ ´ë°³´Â Á÷°æ 2-8cmÀÌ´Ù. Çö¹Ì°æÀûÀ¸·Î »óÇÇ ¼¼Æ÷¿Í °£Áú ¼¼Æ÷·Î ±¸¼ºµÇ¾î ÀÖ°í »óÇÇ ¼¼Æ÷´Â ¾ãÀº È£»ê¼º ¼¼Æ÷Áú°ú Ÿ¿øÇü ¼¼Æ÷ÇÙÀ» °®´Âµ¥ Ư¡ÀûÀÎ ¼¼Æ÷ÇÙÀÇ "±¸" Áï "Ä¿ÇÇ ¾Ë" ¸ð¾çÀ» ÇÏ°Ô µÈ´Ù. °£Áú ¼¼Æ÷´Â ³­Æ÷¸· ¼¼Æ÷¸¦ ´à±âµµ ÇÑ´Ù. ´Ù¸¥ Á¾¾ç ƯÈ÷ Á¡¾×¼º ³¶¼±Á¾À̳ª ³¶¼º ±âÇüÁ¾°ú ÇÔ²² ¹ß»ýÇÏ´Â °ÍÀÌ Àß ¾Ë·ÁÁ® ÀÖ´Ù.
  • broad based tumor
    ±âÀúºÎ°¡ ³ÐÀº Á¾¾ç
  • calcified epithelial odontogenic tumor
    ¼®È¸È­ »óÇǼº Ä¡¼º Á¾¾ç
  • carotid body tumor
    °æµ¿¸Æ ¼Òü Á¾¾ç
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
receptors, corticotropin Cell surface receptors that bind corticotropin (acth, adrenocorticotropic hormone) with high affinity and trigger intracellular changes. Pharmacology suggests there may be multiple acth receptors. An acth receptor has been cloned and belongs to a subfamily of g-protein-coupled receptors. In addition to the adrenal cortex, acth receptors are found in the brain and immune systems.
(12 Dec 1998)
receptors, corticotropin-releasing hormone Cell surface proteins that bind corticotropin-releasing hormone with high affinity and trigger intracellular changes which influence the behaviour of cells. The corticotropin releasing-hormone receptors on anterior pituitary cells mediate the stimulation of corticotropin release by hypothalamic corticotropin releasing factor. The physiological consequence of activating corticotropin-releasing hormone receptors on central neurons is not well understood.
(12 Dec 1998)
receptors, cxcr4 Seven-transmembrane G-protein-coupled receptors for alpha-chemokines. They also function as fusion cofactors for T-cell-tropic HIV-1 strains.
(12 Dec 1998)
receptors, cyclic AMP Cell surface proteins that bind cyclic AMP with high affinity and trigger intracellular changes which influence the behaviour of cells. The best characterised cyclic AMP receptors are those of the slime mold dictyostelium discoideum. The transcription regulator cyclic AMP receptor protein of prokaryotes is not included nor are the eukaryotic cytoplasmic cyclic AMP receptor proteins which are the regulatory subunits of cyclic AMP-dependent protein kinases.
(12 Dec 1998)
receptors, cytoadhesin A group of integrins that includes the platelet outer membrane glycoprotein gpiib-iiia (platelet glycoprotein gpiib-iiia complex) and the vitronectin receptor (receptors, vitronectin). They play a major role in cell adhesion and serve as receptors for fibronectin, von willebrand factor, and vitronectin.
(12 Dec 1998)
receptors, cytokine Cell surface proteins that bind cytokines and trigger intracellular changes influencing the behaviour of cells.
(12 Dec 1998)
receptors, cytoplasmic and nuclear Proteins in the cytoplasm or nucleus that specifically bind signalling molecules and trigger changes which influence the behaviour of cells. The major groups are the steroid hormone receptors, which usually are found in the cytoplasm, and the thyroid hormone receptors, which usually are found in the nucleus. Receptors, unlike enzymes, generally do not catalyze chemical changes in their ligands.
(12 Dec 1998)
receptors, dopamine Cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behaviour of cells.
(12 Dec 1998)
receptors, dopamine d1 A class of dopamine receptors identified by their binding profiles for synthetic ligands, their molecular biology, and, perhaps, by their mode of action.
(12 Dec 1998)
receptors, dopamine d2 A class of dopamine receptors identified by their binding profiles for synthetic ligands, their molecular biology, and, perhaps, their mode of action.
(12 Dec 1998)
receptors, drug Proteins that bind specific drugs with high affinity and trigger intracellular changes influencing the behaviour of cells. Drug receptors are generally thought to be receptors for some endogenous substance not otherwise specified.
(12 Dec 1998)
receptors, eicosanoid Cell surface proteins that bind eicosanoids with high affinity and trigger intracellular changes influencing the behaviour of cells. Among the eicosanoid receptors are receptors for the prostaglandins, thromboxanes, and leukotrienes.
(12 Dec 1998)
receptors, endothelin Cell surface proteins that bind endothelin with high affinity and trigger intracellular changes which influence the behaviour of cells.
(12 Dec 1998)
receptors, erythropoietin Cell surface proteins that bind erythropoietin with high affinity and trigger intracellular changes influencing the behaviour of cells.
(12 Dec 1998)
receptors, estradiol Cytoplasmic proteins that bind estradiol, migrate to the nucleus, and regulate DNA transcription.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á